Naslov
Safety - are there any differences among novel antipsychotics

Autori
Folnegović-Šmalc, Vera ; Mimica, Ninoslav

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni

Izvornik
Neurologia Croatica 51 (Suppl. 1) - Proceedings of the 42nd International Neuropsychiatric Pula Symposium / Barac, Boško ; Huber, Gerd ; Lechner, Helmut ; Muačević, Vasko - Zagreb : Denona, 2002, 104-104

Skup
42nd International Neuropsychiatric Pula Symposium

Mjesto i datum
Pula, Hrvatska, 29.05.2002. - 01.06.2002

Vrsta sudjelovanja
Predavanje

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
safety; novel antipsychotics

Sažetak
The novel antipsychotics are concidered as a safe medication, but recentlythere is increasing number of case reports and small retrospective studies suggesting that atypical antipsychotics may be associated with new-onset Type II Diabetes mellitus (DM) or diabetic ketoacidosis (DKA). Most, but not all, recent literature points to an increased incidence and prevalence of DM with clozapine and olanzapine. The precise mechanism of this suspected adverse drug reaction has not yet been alucidated and is currently being investigated further. In the meantime careful blood glucose monitoring in those with existing diabetes is essential but also monitoring of body mass index (BMI) and glocose levels in all patinents on clozapine and olanzapine is advised. It seems logical that no new diabetes patinets should be treated with these drugs. In patints with risk factors (DM family history, obesity, negroid, inactivity) atypicals with low diabetogenic profile are advised.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA